Lazard ZaWaunyka W, Olmsted-Davis Elizabeth A, Salisbury Elizabeth A, Gugala Zbigniew, Sonnet Corrine, Davis Eleanor L, Beal Eric, Ubogu Eroboghene E, Davis Alan R
Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Clin Orthop Relat Res. 2015 Sep;473(9):2790-806. doi: 10.1007/s11999-015-4323-9.
Heterotopic ossification (HO) is the process of bone formation at a nonskeletal site. Recently, we showed that the earliest steps occur in sensory nerves. We now extend these studies by identifying unique osteogenic progenitors within the endoneurial compartment of sensory nerves.
QUESTIONS/PURPOSES: We asked: (1) What is the nature of the osteoprogenitor in the endoneurium of peripheral nerves? (2) How do osteoprogenitors travel from the nerve to the site of new bone formation?
HO was induced by intramuscular injection of Ad5BMP-2-transduced cells in mice. Osteoprogenitors were identified through immunohistochemistry and then quantified and further characterized by fluorescence-activated cell sorting and immunocytochemistry. The kinetics of the appearance of markers of extravasation was determined by quantitative reverse transcription-polymerase chain reaction. In each experiment mice were injected with bone morphogenetic protein-2 (BMP-2)-producing cells (experimental) or with cells transduced with empty vector or, in some cases, a group receiving no injection (control).
Induction of HO leads to the expression, within 24 hours, of osteoblast-specific transcription factors in cells in the endoneurium followed by their coordinate disappearance from the nerve at 48 hours. They reappear in blood also at 48 hours after induction. During vessel entrance they begin to express the tight junction molecule, claudin 5. The cells expressing both the osteoblast-specific transcription factor, osterix, as well as claudin 5, then disappear from circulation at approximately 3 to 4 days by extravasation into the site of new bone formation. These endoneurial osteoprogenitors express neural markers PDGFRα, musashi-1, and the low-affinity nerve growth factor receptor p75(NTR) as well as the endothelial marker Tie-2. In a key experiment, cells that were obtained from mice that were injected with cells transduced with an empty vector, at 2 days after injection, contained 0.83% (SD, 0.07; 95% confidence interval [CI], 0.59-1.05) cells expressing claudin 5. However, cells that were obtained from mice 2 days after injection of BMP-2-producing cells contained 4.5% cells expressing claudin 5 (SD, 0.72%; 95% CI, 2.01-6.94; p < 0.0015). Further analysis revealed that all of the cells expressing claudin 5 were found to be positive for osteoblast-specific markers, whereas cells not expressing claudin 5 were negative for these same markers.
The findings suggest that the endoneurial progenitors are the major osteogenic precursors that are used for HO. They exit the nerve through the endoneurial vessels, flow through vessels to the site of new bone formation, and then extravasate out of the vessels into this site.
The biogenesis of osteoblasts in HO is very different than expected and shows that HO is, at least in part, a neurological disorder. This could result in a major shift in orthopaedic methodologies to prevent or treat this disease. The fact that nerves are intimately involved in the process may also provide clues that will lead to an explanation of the clinical fact that HO often occurs as a result of traumatic brain injury.
异位骨化(HO)是在非骨骼部位形成骨的过程。最近,我们发现最早的步骤发生在感觉神经中。我们现在通过鉴定感觉神经内膜隔室内独特的成骨祖细胞来扩展这些研究。
问题/目的:我们提出以下问题:(1)周围神经内膜中成骨祖细胞的性质是什么?(2)成骨祖细胞如何从神经迁移到新骨形成部位?
通过在小鼠肌肉内注射腺病毒5型骨形态发生蛋白2(Ad5BMP-2)转导的细胞诱导HO。通过免疫组织化学鉴定成骨祖细胞,然后通过荧光激活细胞分选和免疫细胞化学进行定量和进一步表征。通过定量逆转录-聚合酶链反应确定外渗标志物出现的动力学。在每个实验中,给小鼠注射产生骨形态发生蛋白2(BMP-2)的细胞(实验组)或用空载体转导的细胞,在某些情况下,一组不注射(对照组)。
HO的诱导导致在24小时内神经内膜中的细胞表达成骨细胞特异性转录因子,随后在48小时时它们从神经中协同消失。诱导后48小时它们也出现在血液中。在进入血管期间,它们开始表达紧密连接分子claudin 5。同时表达成骨细胞特异性转录因子osterix以及claudin 5的细胞,然后在大约3至4天时通过外渗进入新骨形成部位而从循环中消失。这些神经内膜成骨祖细胞表达神经标志物血小板衍生生长因子受体α(PDGFRα)、神经干细胞标志物musashi-1和低亲和力神经生长因子受体p75(NTR)以及内皮标志物Tie-2。在一项关键实验中,在注射后2天从注射用空载体转导的细胞的小鼠中获得的细胞,含有0.83%(标准差,0.07;95%置信区间[CI],0.59 - 1.05)表达claudin 5的细胞。然而,在注射产生BMP-2的细胞后2天从小鼠中获得的细胞含有4.5%表达claudin 5的细胞(标准差,0.72%;95% CI,2.01 - 6.94;p < 0.0015)。进一步分析显示,所有表达claudin 5的细胞均被发现对成骨细胞特异性标志物呈阳性,而不表达claudin 5的细胞对这些相同标志物呈阴性。
这些发现表明神经内膜祖细胞是用于HO的主要成骨前体。它们通过神经内膜血管离开神经,通过血管流向新骨形成部位,然后从血管外渗到该部位。
HO中成骨细胞的生物发生与预期非常不同,表明HO至少部分是一种神经疾病。这可能导致骨科预防或治疗该疾病的方法发生重大转变。神经密切参与该过程这一事实也可能提供线索,从而解释HO常因创伤性脑损伤而发生这一临床事实。